The dilemma of new drugs. Are costs rising faster than effectiveness?

abstract：:Epidural analgesia and intravenous analgesia with opioids are two techniques for providing pain relief for women in labour. Labour pain is comparable to surgical pain in its severity, and epidural analgesia provides better relief from this pain than intravenous analgesia; a meta-analysis quantified this improvement to...

journal_title：PharmacoEconomics

authors： Huang C,Macario A

更新日期：2002-01-01 00:00:00

abstract：:Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and fu...

journal_title：PharmacoEconomics

authors： Campbell JD,Ramsey SD

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic ...

journal_title：PharmacoEconomics

authors： Grutters JP,Sculpher M,Briggs AH,Severens JL,Candel MJ,Stahl JE,De Ruysscher D,Boer A,Ramaekers BL,Joore MA

更新日期：2013-02-01 00:00:00

abstract：:Clinical studies have shown that the combination of an inhaled corticosteroid (ICS) and a long-acting beta(2)-adrenoceptor agonist (LABA) for patients with asthma is more effective than the use of ICS alone in equivalent or higher doses, as well as the use of other combinations. However, the relatively higher acquisit...

journal_title：PharmacoEconomics

authors： Akazawa M,Stempel DA

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that have therapeutic added value in com...

journal_title：PharmacoEconomics

authors： Hoomans T,Severens JL,van der Roer N,Delwel GO

更新日期：2012-03-01 00:00:00

abstract：OBJECTIVE:To estimate indirect costs in Spanish ambulatory patients with HIV/AIDS and to identify changes in employment status and their current QOL. METHOD:Information was obtained through 32 interviews/enquiries carried out with ambulatory patients receiving medical attention at Gregorio Marañón and Puerta de Hierro...

journal_title：PharmacoEconomics

authors： Oliva J,Roa C,del Llano J

更新日期：2003-01-01 00:00:00

abstract：:Productivity costs are frequently omitted from economic evaluations, despite their often strong impact on cost-effectiveness outcomes. This neglect may be partly explained by the lack of standardization regarding the methodology of estimating productivity costs. This paper aims to contribute to standardization of prod...

journal_title：PharmacoEconomics

authors： Krol M,Brouwer W

更新日期：2014-04-01 00:00:00

abstract：:The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment costs, while indirect costs consisted mainly of costs incurred as a result of work time lost, as well as costs related to premature retirement and premature mortali...

journal_title：PharmacoEconomics

authors： Brecht JG,Poldrugo F,Schädlich PK

更新日期：1996-11-01 00:00:00

abstract：:As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresecta...

journal_title：PharmacoEconomics

authors： Witlox WJA,van Asselt ADI,Wolff R,Armstrong N,Worthy G,Chalker A,Buksnys T,Stirk L,Kleijnen J,Joore MA,Grimm SE

更新日期：2020-04-01 00:00:00

abstract：OBJECTIVES:Discrete choice experiments (DCEs) are increasingly advocated as a way to quantify preferences for health. However, increasing support does not necessarily result in increasing quality. Although specific reviews have been conducted in certain contexts, there exists no recent description of the general state ...

journal_title：PharmacoEconomics

authors： Soekhai V,de Bekker-Grob EW,Ellis AR,Vass CM

更新日期：2019-02-01 00:00:00

abstract：BACKGROUND:Within the framework of economic evaluations, the transferability of utility scores between jurisdictions remains unclear. The EQ-5D is a generic instrument for measuring health-related quality of life in economic evaluations, which can be used for comparing utility scores across countries. At present, the E...

journal_title：PharmacoEconomics

authors： Knies S,Evers SM,Candel MJ,Severens JL,Ament AJ

更新日期：2009-01-01 00:00:00

abstract：:The elderly are a heterogeneous population group who range from well and completely independent individuals to a smaller proportion who are frail, require help and are high users of the healthcare system. Since health is a state of well-being which includes the domains of social, spiritual, psychological and physical ...

journal_title：PharmacoEconomics

authors： Turpie I,Strang D,Darzins P,Guyatt G

更新日期：1997-11-01 00:00:00

abstract：:Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision an...

journal_title：PharmacoEconomics

authors： Ara R,Rowen D,Mukuria C

更新日期：2017-12-01 00:00:00

abstract：:Measuring health-related quality of life in patients with cancer has focused primarily on the development of reliable and valid instruments (questionnaires), and on the effect of chemotherapy in phase III clinical trials. From this research several important lessons have emerged, such as: (i) the need to measure multi...

journal_title：PharmacoEconomics

authors： Osoba D

更新日期：1995-04-01 00:00:00

abstract：:Non-melanoma skin cancer (NMSC) and actinic keratosis are becoming an increasingly important healthcare problem. There are approximately 1 million cases of NMSC in the US each year, primarily basal cell carcinomas, and the incidence is increasing. Although NMSC is significant in terms of both health risk and the resou...

journal_title：PharmacoEconomics

authors： Higashi MK,Veenstra DL,Langley PC

更新日期：2004-01-01 00:00:00

abstract：:In an attempt to obtain an appropriate estimate of the excess costs of production losses arising from morbidity in patients with diabetes, we compared the number of sick days and permanently disabled individuals in a diabetic population and the corresponding general population. These comparisons show that the rate of ...

journal_title：PharmacoEconomics

authors： Persson U

更新日期：1995-01-01 00:00:00

abstract：BACKGROUND:Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important in selecting appropriate...

journal_title：PharmacoEconomics

authors： Reboli AC,Rotstein C,Kett DH,Maschio M,Cartier S,Chambers R,Tarallo M

更新日期：2011-08-01 00:00:00

abstract：:Clinical and economic factors that are important to consider when selecting anaesthesia for day-case surgery can differ from those for inpatient anaesthesia. Patients undergoing day-case surgery tend to be healthier and have shorter durations of surgery. They expect less anxiety before surgery, amnesia for the surgica...

journal_title：PharmacoEconomics

authors： Eger EI,White PF,Bogetz MS

更新日期：2000-03-01 00:00:00

abstract：:Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Novosel S,Torrance G,Streiner D

更新日期：1995-07-01 00:00:00

abstract：:Answering the demanding questions asked of pharmacotherapy in the 21st century will require more reliance on the disciplines of pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology can help assess patterns and appropriateness of drug utilisation, provide explanations for poor compliance, quantify the frequ...

journal_title：PharmacoEconomics

authors： Avorn J

更新日期：2004-01-01 00:00:00

abstract：OBJECTIVE:To assess the economic efficiency of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac and piroxicam in the UK for the treatment of patients with osteoarthritis and the impact on the NHS budget of substituting nonselective NSAIDs with meloxicam. Methods and perspective: A decision an...

journal_title：PharmacoEconomics

authors： Tavakoli M

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:The high consumption of hypolipidaemic agents warrants the study of the costs caused by these medicines being inadequately prescribed. OBJECTIVE:To quantify the economic cost generated in 1 year in primary care by inadequate (or unnecessary) prescriptions for hypolipidaemic drugs. METHODS:A cross-sectional...

journal_title：PharmacoEconomics

authors： Ballesteros LC,Fernández San Martín MI,Sanz Cuesta T,Escortell Mayor E,López Bilbao C

更新日期：2001-01-01 00:00:00

abstract：:Pneumocystis carinii pneumonia (PCP) is the most common severe opportunistic infection, and one of the most costly, among people with AIDS. Over 50% of patients experience toxic effects of the major anti-PCP medications- cotrimoxazole (trimethoprim-sulfamethoxazole) and pentamidine. Recently, the US Food and Drug Admi...

journal_title：PharmacoEconomics

authors： Zarkin GA,Bala MV,Wood LL,Bennett CL,Simpson K,Dohn MN

更新日期：1996-06-01 00:00:00

abstract：:Peptic ulcer disease (PUD) is a common medical problem costing billions of dollars annually around the world. Since the availability of the first histamine H2-receptor antagonist, cimetidine, many economic analyses have been conducted to compare the impact of this drug class on resource consumption. H2-Antagonists h...

journal_title：PharmacoEconomics

authors： Tucker PP,Nash DB

更新日期：1994-04-01 00:00:00

abstract：:Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modell...

journal_title：PharmacoEconomics

authors： Husbands S,Jowett S,Barton P,Coast J

更新日期：2017-06-01 00:00:00

abstract：:Hepatitis B virus (HBV) infection is an important public health problem all over the world. Vaccination is one way to prevent it, and several strategies can be used depending on endemicity, the main pattern of HBV transmission and the demographic structure of the population. In this study, an economic comparison of 3 ...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Garuz R,Rovira J,Antón F,Trinxet C,Navas E,Salleras L

更新日期：1995-05-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Accurate prediction of relevant outcomes is important for targeting therapies and to support health economic evaluations of healthcare interventions in patients with diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) risk equations are some of the most frequently used risk equation...

journal_title：PharmacoEconomics

authors： Laxy M,Schöning VM,Kurz C,Holle R,Peters A,Meisinger C,Rathmann W,Mühlenbruch K,Kähm K

更新日期：2019-12-01 00:00:00

abstract：:The aim of this article was to perform a detailed methodological review of models used to estimate the cost effectiveness of drug treatment regimens for HIV infection in Europe and North America and assess the relationship between the different modeling approaches or key structural assumptions and the results. Electro...

journal_title：PharmacoEconomics

authors： Mauskopf J

更新日期：2013-11-01 00:00:00

abstract：:Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article. ...

journal_title：PharmacoEconomics

authors： Wehler E,Boytsov N,Nicolay C,Herrera-Restrepo O,Kowal S

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Assessment of health state and health-related quality of life (HR-QOL) are limited by a child's age and cognitive ability. Parent-proxy reports are known to differ from children's reports. Simultaneous assessment using a parent-child dyad is an alternative approach. OBJECTIVE:Our objective was to assess the...

journal_title：PharmacoEconomics

authors： Ungar WJ,Boydell K,Dell S,Feldman BM,Marshall D,Willan A,Wright JG

更新日期：2012-08-01 00:00:00